Hospital Ruber Internacional
O custo da imunoterapia na Espanha geralmente varia de $12,000 a $25,000. Os preços variam dependendo do tipo de imunoterapia utilizada (tais como anticorpos monoclonais, inibidores de checkpoint ou terapia com células CAR-T), o número de ciclos de tratamento, a clínica e a expertise do médico responsável. Nos Estados Unidos, o preço médio é $30,000 (de acordo com a American Cancer Society). Isso significa que a imunoterapia na Espanha pode ser cerca de 38% mais barata do que nos EUA.
As clínicas espanholas geralmente incluem consulta inicial, testes diagnósticos, administração de medicamentos, monitoramento durante o tratamento e visitas de acompanhamento agendadas no custo total. Nos EUA, o preço listado geralmente cobre apenas a medicação, com cobranças separadas para consultas médicas, exames laboratoriais e serviços de infusão. Sempre confirme exatamente o que está incluído em cada clínica.
Por que escolher a Espanha para imunoterapia?
Acesse soluções avançadas de imunoterapia em clínicas de confiança [a partir de-custo].
| Turquia | Áustria | Espanha | |
| Imunoterapia | de $2,200 | de $30,000 | de $12,000 |
| Terapia com Bacilo de Calmette-Guérin (BCG) | de $1,200 | de $2,400 | de $3,200 |
| Terapia biológica | de $5,500 | de $20,000 | de $15,000 |
| Imunoterapia para o cancro do pulmão | de $18,000 | de $30,000 | de $30,000 |
| Imunoterapia para o cancro da próstata | de $12,000 | de $30,000 | de $35,000 |
A Bookimed não adiciona taxas extras aos preços de Imunoterapia. As tarifas vêm das listas oficiais das clínicas. O pagamento é feito diretamente na clínica na chegada.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais em Imunoterapia e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de Imunoterapia.
O Dr. Graupera chefia o Departamento de Hematologia e Oncologia no Sant Joan De Déu – um dos principais hospitais infantis da Europa. Sua pesquisa foca nos tratamentos para o câncer pediátrico.
Dr. Lucía González Cortijo is a medical oncologist with more than 20 years of experience. She has led the Medical Oncology Department at Hospital Universitario Quirónsalud Madrid since 2020. Her focus areas include breast and gynecologic cancers. She also works in precision oncology, targeted therapies, and immunotherapy.
She has been Principal Investigator in more than 20 Phase II–III clinical trials. She has also served as sub-investigator in over 50 international trials. She previously worked at Quirónsalud Madrid from 2009 to 2020. Before that, she was at MD Anderson Cancer Center Madrid from 2002 to 2009.
She holds an MD and a PhD (cum laude) from the Autonomous University of Madrid. She completed her Medical Oncology specialty training at Hospital 12 de Octubre. She also earned a Master’s in Molecular Oncology. She is a member of SEOM, ESMO, ASCO, and GEICAM. She is a university lecturer.
Líder de renome mundial em Leucemia Linfocítica Crónica (LLC) – O Professor Bosch lidera mais de 80 ensaios clínicos sobre novos tratamentos.
Investigador Principal em ensaios clínicos com foco em imunoterapia para cânceres ginecológicos – A Dra. Oaknin lidera pesquisa de ponta no Hospital Quirón Barcelona.
Spain provides advanced immunotherapy options including checkpoint inhibitors, CAR T-cell therapy, and monoclonal antibodies. Leading centers like Centro Médico Teknon and Clínica Universidad de Navarra utilize biomarker-driven precision oncology to treat lung, breast, and hematologic cancers with drugs like Keytruda and Opdivo.
Bookimed Expert Insight: Spain stands out globally for institutional clinical trials. At Quironsalud Madrid, patients may qualify for free access to next-generation immunotherapy through active trials. Always confirm if your specific cancer markers, like PD-L1 or MSI, have been tested. These results often dictate which high-cost drugs clinics will approve for your case.
Patient Consensus: Patients recommend confirming the exact drug protocol and biomarker requirements early. Many highlight the importance of reporting immune-related side effects, such as fatigue or rashes, immediately to the clinical team.
Spain features internationally accredited institutions specialized in cutting-edge oncological care. Top hospitals for cancer immunotherapy include Clinica Universidad de Navarra, Centro Medico Teknon, and MD Anderson Cancer Center Madrid. These centers offer advanced checkpoint inhibitors, personalized biomarker matching, and access to international clinical trials.
Bookimed Expert Insight: Spain's oncology landscape is unique because private centers like Clinica Universidad de Navarra often lead in JCI certifications. However, our data shows institutional clusters in Madrid and Barcelona provide the best access to multidisciplinary tumor boards. For complex immunotherapy, look for clinics like Quironsalud Madrid that host over 20+ active Phase II and III trials.
Patient Consensus: Patients prioritize clinics with in-house molecular labs for PD-L1 testing and tumor board reviews. Many suggest visiting these reference centers in Madrid or Barcelona specifically for treatment planning before starting regimens.
International patients can access immunotherapy clinical trials in Spain through private centers and research hubs, though eligibility is determined on a case-by-case basis. Spain leads European oncology research, with clinics like Quironsalud Madrid offering free treatment for eligible participants in active Phase I-III studies.
Bookimed Expert Insight: While major centers like Quironsalud Barcelona and Teknon Medical Center serve thousands of international patients, trial success often depends on specialized units. For instance, Dr. Francesc Bosch at Quironsalud Barcelona currently manages over 80 Phase I-III trials. Patients should target institutions where principal investigators have a high volume of registration-enabling trials, as these clinics often have the most robust infrastructure for international enrollment and safety reporting.
Patient Consensus: Success depends on having a complete medical dossier ready, including translated pathology reports and specific biomarker panels like PD-L1 or MSI. Many find that early-phase trials are logistically difficult due to frequent monitoring, making later-phase studies more practical for those traveling from abroad.